GSK unit Stiefel snags rights to skin drug for CAD$35M

Stiefel Laboratories has injected a new drug in mid-stage development into its dermatology pipeline. The company, a unit of GlaxoSmithKline ($GSK), has ponied up CAD$35 million ($33.9 million) in an u…
Read the full story: News